Surrey Heartlands

Joint Formulary & PAD

Bempedoic acid with ezetimibe - Lipid modification

You are here : Home > Formulary Search > Bempedoic acid with ezetimibe - Lipid modification

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
NICE
SPC
Restrictions / Comments :
Documents :
 
Evidence Review
Bempedoic Acid and ezetimibe - Change in colour classification - December 2024.pdf

Documentation

Evidence Review
Bempedoic acid with ezetimibe - briefing paper - Jul 2021
Webpage
NICE TA694 - Bempedoic acid with ezetimibe for primary hypercholesterolaemia or mixed dyslipidaemia - Apr 2021
Webpage
Statin Intolerance Pathway (NHS England AAC programme)
Webpage
National Guidance for Lipid Management for Primary and Secondary Prevention of CVD (NHS England AAC programme)

PAD Profile

ChemicalSubstance :
Bempedoic acid with ezetimibe
Indication :
Lipid modification
Group Name :
Keywords :
Primary hypercholesterolaemia, mixed dyslipidaemia, lipid-lowering, lipid lowering, raised cholesterol, high cholesterol
Brand Names Include :
Nustendi
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Lipid modification
Supporting Documents :
5

Other Indications

Below are listed other indications that Bempedoic acid with ezetimibe is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Lipid modification.

Committee Recommendations (1)

04 Dec 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a GREEN traffic light status for bempedoic Acid with ezetimibe in line with NICE guidance (TA694).

 Please follow the guidance in the SPC and the National Lipid Management pathway for advice on initial and onward monitoring requirements.

 Note: Anaemia is a common side-effect of bempedoic acid. For patients where a reduction in haemoglobin (Hb) may be of concern, consider a full blood count (FBC) at 3 months and annually thereafter.